<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ADC61BCE-C347-47C2-97A2-524F79092505"><gtr:id>ADC61BCE-C347-47C2-97A2-524F79092505</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Lewis</gtr:otherNames><gtr:surname>Vetrie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D4117CD5-A241-4E15-BD25-850900831C11"><gtr:id>D4117CD5-A241-4E15-BD25-850900831C11</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:surname>West</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FJ008605%2F1"><gtr:id>0DE453CE-2AA2-43FF-AB47-DDD001E16535</gtr:id><gtr:title>The role of H2B ubiquitination in genome organisation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/J008605/1</gtr:grantReference><gtr:abstractText>The expression of genes within our cells requires the transcription of an RNA copy of the gene DNA, which is then translated to make the encoded protein. The transcription of genes in eukaryotes occurs within the context of chromatin, a complex between DNA and histone proteins, which packages the DNA. The histones also play important regulatory roles that govern chromatin structure and the binding of regulatory proteins, which in turn control gene transcription. This regulation mostly arises through a large number of post translational modifications of the histones themselves. Each of these modifications is associated with a particular chromatin state or regulatory event. This has given rise to the idea of a &amp;quot;histone code&amp;quot;, which has some control over access to the underlying genetic code.

In this genomic era, it is now possible to profile the distribution of modified histones and chromatin regulatory proteins across the whole human genome. Recent studies are finding that the genome is organised into &amp;quot;domains&amp;quot; that share distinct chromatin states. These domains appear to coordinate the regulation of gene transcription. The integrity of chromatin domains can require the setting of boundaries between transcriptionally permissive and repressive chromatin states. DNA sequences known as chromatin barrier elements can establish these boundaries. 

This proposal follows up on our recent finding that barrier elements use a particular chromatin modification, the ubiquitination of histone H2B, to establish chromatin boundaries. Depletion of H2B ubiquitination disables barrier activity, resulting in the spread of repressive chromatin and transcriptional silencing of nearby genes. In this proposal, we aim to determine whether H2B ubiquitination is a common hallmark of chromatin boundaries across the human genome. We also aim to define the contribution of this mark to boundary integrity and chromosomal domain organisation. This study will involve mapping the distribution of modified histones and chromatin barrier proteins across the whole human genome. We will determine whether the depletion of H2B ubiquitination results in the failure of chromatin boundaries in humans, and we will determine the barrier activities of novel boundary elements.</gtr:abstractText><gtr:technicalSummary>Genomic maps of chromatin modifications have provided evidence for the partitioning of genomes into domains of distinct chromatin states, which may assist coordinated gene regulation. The maintenance of chromatin domain integrity can require the setting of boundaries. We have recently identified H2B ubiquitination as an important regulator of chromatin boundary elements at the chicken beta-globin gene cluster. H2B ubiquitination is required for the chromatin barrier activity of the HS4 boundary element. Depletion of H2B ubiquitination results in a collapse of the active histone modification signature that characterizes boundary elements. The loss of boundary function leads to the spreading of heterochromatin-associated histone modifications with transcriptional silencing of neighbouring gene loci. 

This proposal applies what we have learned from our detailed analysis of the chicken HS4 element and our pilot study of human chromatin boundaries. The proposal will combine the advantages of high throughput epigenomics with experimental biology and functional assays to identify barrier elements marked with ubiquitinated H2B and define the contribution of this mark to boundary integrity and chromosomal domain organisation in humans.</gtr:technicalSummary><gtr:potentialImpactText>Chromatin barrier elements can protect against chromosomal position effect, thereby enabling the stable expression of transgenes from plasmid and viral vectors. Transgenic technology is crucial for bioscience companies developing and producing recombinant proteins in mammalian cells for therapeutic purposes, often referred to as &amp;quot;biologics&amp;quot;. Many companies use large scale mammalian cell culture systems, but increasingly, companies are generating transgenic animals that express the protein of interest in their milk, including sheep, cattle, goats and rabbits. Examples of therapeutic proteins currently in development include lower dosing insulin analogues, second generation erythropoietins, anti-arthritic beta interferons, albumin free anti-haemophilic factors and monoclonal antibodies. UK-based companies involved in the development and/or manufacture of therapeutic proteins include Eden Biodesign, Celltech, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, Lonza and MedImmune, to name just a few. Improved barrier elements with easier licensing in the UK could help speed up the development of new therapeutic proteins by improving reproducibility of protein production and reducing the time taken to screen cells or animals for protein expression.
The development of improved viral vectors is also priority for those working on gene therapy approaches. Strong transcriptional enhancer elements are often used to drive transgene expression in order to overcome chromosomal position effect. However, these enhancers have been shown to disregulate genes near the vector integration site, resulting in cellular transformation and cancer promotion. The incorporation of barrier elements to preserve transgene expression and minimise non-specific activation of cellular genes could provide significant. The identification of novel barrier elements in this project could ultimately lead to safer and more effective gene therapy vectors, thus improving the treatments available for seriously ill patients.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>681190</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCB Celltech</gtr:department><gtr:description>Identification of novel chromatin opening elements that facililtate stable gene expression.</gtr:description><gtr:id>751FD313-8EAB-455C-A1C7-3CB994C9C73E</gtr:id><gtr:impact>In progress
First publication at draft stage (awaiting legal approval)</gtr:impact><gtr:partnerContribution>Financial. Co-supervision. Technical expertise. Reagents.</gtr:partnerContribution><gtr:piContribution>Supervise PhD student. Provide additional bioinformatic support.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Glasgow Science Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>21F72185-4C8C-4D03-BD27-D8EA840D8776</gtr:id><gtr:impact>Event attended by over 2000 members of the public

Engagement of local children in science, meeting real scientists.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.glasgowsciencefestival.org.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow University Science Sunday</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B6F38C71-A2FA-47F8-82B0-39DB82789BBD</gtr:id><gtr:impact>Attended by over a 1000 members of the public

Engagement of children in science.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.glasgowsciencefestival.org.uk/events/sciencefestival/events/allages/13-sciencesunday/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Our findings have guided the identification of novel gene regulatory elements that could assist stable transgene gene expression during the production of recombinant biologics in mammalian cells.
We have an active collaboration with a UK Pharma company to exploit this.</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>2C06E583-3FA7-48DF-8C93-808588893709</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Our previous work identified a key role for histone H2B ubiquitination in the establishment of an active chromatin state at the paradigm chicken HS4 insulator element during chromatin boundary formation and maintenance. This project explores whether similar events occur across the human genome and what role this has in genome organisation. We have found
1) It is not possible, with current reagents and techniques, to map H2B ubiquitination at chromatin boundaries (more detail below)
2) We have generated genome wide maps for H2Bub and repressive chromatin marks of a quality that far exceeds that reported to date
3) We have identified a range of candidate chromatin boundary elements from these data
4) We have established cell line models for regulated silencing of the H2B ubiquitin ligase RNF20 and have mapped repressive chromatin marks across the genome after short and long term depletion of RNF20
5) During the course of our bioinformatic work and in collaborations with other projects within the team, we have developed a novel bioinformatic approach to identify and refine transcription factor binding sites by combining protein structural modelling and ChIP-seq data. This is currently being written up for publication.</gtr:description><gtr:exploitationPathways>The main impact we have at this time is the high quality chromatin domain data we have generated. From this we have identified a list candidate chromatin boundary elements that meet different sets of criteria. These are being taken forward in three active projects
i) BBSRC PhD project using CRISPR effectors to study candidate chromatin boundary elements (outcomes over next 12 months)
ii) PhD project to study the ability of candidate chromatin boundary elements to protect transgenes from chromosomal silencing in a a novel high throughput assay (outcomes over next 12-18 months)
iii) Industrial collaboration to employ candidate chromatin boundary elements in biopharmaceutical production

Depending on the outcome of these ongoing analyses, we would seek to IP protect and then exploit novel chromatin boundary elements in genetic therapeutic and biotech applications with exisiting and new collaborations.</gtr:exploitationPathways><gtr:id>390CD6BC-48EB-4C59-8AA4-6DA25173E9FD</gtr:id><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.gla.ac.uk/researchinstitutes/cancersciences/research/units/epigenetics/adamwest/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/657C7477-D19E-4861-9CA1-A33B04EBF487"><gtr:id>657C7477-D19E-4861-9CA1-A33B04EBF487</gtr:id><gtr:title>Chromatin looping defines expression of TAL1, its flanking genes, and regulation in T-ALL.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07c2a4af9f42a88efefb696767d62dd9"><gtr:id>07c2a4af9f42a88efefb696767d62dd9</gtr:id><gtr:otherNames>Zhou Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/086A4A1C-6DDE-4F88-97EA-D7A2A14E0156"><gtr:id>086A4A1C-6DDE-4F88-97EA-D7A2A14E0156</gtr:id><gtr:title>USF binding sequences from the HS4 insulator element impose early replication timing on a vertebrate replicator.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1d1dfb53379d034a6ec9c2f6e1c805b"><gtr:id>f1d1dfb53379d034a6ec9c2f6e1c805b</gtr:id><gtr:otherNames>Hassan-Zadeh V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/76AD5738-A21F-411A-A0B6-47EC9BCF2B03"><gtr:id>76AD5738-A21F-411A-A0B6-47EC9BCF2B03</gtr:id><gtr:title>Unique reporter-based sensor platforms to monitor signalling in cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/faaa4e342f816e833b84545cabd5ab5c"><gtr:id>faaa4e342f816e833b84545cabd5ab5c</gtr:id><gtr:otherNames>Jiwaji M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08B1B7C3-98C7-4052-AE5A-CD370CBC227E"><gtr:id>08B1B7C3-98C7-4052-AE5A-CD370CBC227E</gtr:id><gtr:title>The inducible tissue-specific expression of the human IL-3/GM-CSF locus is controlled by a complex array of developmentally regulated enhancers.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6f67df8f0a4808cf26cb69a23272ab7"><gtr:id>d6f67df8f0a4808cf26cb69a23272ab7</gtr:id><gtr:otherNames>Baxter EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/J008605/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>C23BE70F-1EF6-4CC7-88B0-841CB18DD875</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Genetics &amp; development</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B6EF57B2-8ACD-48E6-9B45-98507446B053</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Epigenetics</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>CC10CC12-1D16-48BD-8F66-6A64A651DEAB</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Gene action &amp; regulation</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>D3C718B2-93A6-47C3-A0F0-F426AC23276E</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Genome organisation</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>